Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
How did the 'Berlin patient' rid himself of HIV?

Researchers are closer to unraveling the mystery of how Timothy Ray Brown, the only human cured of HIV, defeated the virus, according to a new study. Although the work doesn’t provide a definitive answer, it rules out one possible explanation.

Published
29 September 2014
From
Science
Doctor treats Ebola with HIV drug in Liberia - seemingly successfully

A doctor in rural Liberia inundated with Ebola patients says he's had good results with a treatment he tried out of sheer desperation: an HIV drug. Dr. Gobee Logan has given the drug, lamivudine, to 15 Ebola patients, and all but two survived. That's a 7% mortality rate whereas across West Africa, the virus has killed 70% of its victims.

Published
27 September 2014
From
CNN
Tybost (Cobicistat) and Vitekta (Elvitegravir) Approved by FDA as Individual HIV Drugs

A next-generation boosting agent and an integrase inhibitor joined the growing ranks of approved HIV medications on Sept. 24, when the U.S. Food and Drug Administration (FDA) stamped its seal of approval on Tybost (known generically as cobicistat) and Vitekta (elvitegravir).

Published
26 September 2014
From
The Body
Gilead’s investigational tenofovir alafenamide (TAF)-based single tablet HIV regimen meets 48-week primary objective in two Phase 3 studies

The studies demonstrated that the single tablet regimen comprising elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and TAF 10 mg (E/C/F/TAF), was non-inferior to Gilead’s Stribild® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) based on the proportion of patients with HIV RNA levels (viral load) of less than 50 copies/mL at 48 weeks of therapy. In addition, E/C/F/TAF demonstrated more favorable renal and bone safety compared to Stribild.

Published
25 September 2014
From
Gilead press release
Gilead's Latest HIV Pill Meets Study Goals

Gilead Sciences Inc. said its new investigational combination pill for HIV met its primary study goals in two late-stage studies, boosting prospects that the biotech company will be able to contain anticipated generic competition to one of its biggest businesses.

Published
24 September 2014
From
Wall Street Journal
HIV Research Fraud Highlights Scramble for Federal Science Grant Money

In the most brazen case of medical research fraud since the 1974 "patchwork mouse" scandal, scientist Dong-Pyou Han has admitted to faking an HIV vaccine experiment to gain federal funding.

Published
24 September 2014
From
Healthline
The Only People Who Have Ever Been Cured of HIV/AIDS

Over the past few years, a tiny number of people appeared to have had active, living, reproducing HIV completely eliminated from their bodies. Here's a quick look at the most solidly documented "functional HIV cure" cases we know of today.

Published
24 September 2014
From
The Body Pro
Has Jacob Zuma hurt the fight against AIDS more than Thabo Mbeki?

Has South African president Jacob Zuma set back the the fight against HIV/AIDS more than his predecessor? Opposition leader Helen Zille believes so but the evidence shows otherwise.

Published
23 September 2014
From
Africa Check
Gilead Sciences: A Preview of Important HIV Drug Study Results

Gilead is running nine phase III studies involving tenofovir alafenamide (TAF), which reflects the importance of the drug to Gilead's future HIV business. It is collecting an enormous amount of clinical data in which to make the case that TAF should be a preferred backbone drug for new and existing HIV patients, as well as patients who cannot use Viread because of pre-existing kidney conditions.

Published
23 September 2014
From
The Street
Guidelines Advise Against Tenofovir for HIV Patients With Kidney Disease

HIV-positive patients who have reduced kidney function should take antiretroviral therapy, but should avoid regimens that contain tenofovir (Viread), according to updated treatment guidelines from the HIV Medicine Association (HIVMA).

Published
22 September 2014
From
The Body Pro

Filter by country